Diligence memo · auto-generated · as of July 2, 2026
I 3 Pharmaceuticals, LLC
I 3 Pharmaceuticals, LLC looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
I 3 Pharmaceuticals, LLC operates in Pharmaceuticals, based in WARMINSTER.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
I 3 Pharmaceuticals, LLC has raised $16M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $16M on 2022-05-06.
Most recent recorded round closed around 2022-05-06.
Valuation (modeled)modeled
Provath models I 3 Pharmaceuticals, LLC at approximately $262M (range $34M–$710M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.02× the median modeled value of Series B Pharmaceuticals companies in 2022–2024 (51 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 4.2 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 63% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 73% of those peers.
Closest niche peers: MedAvail Holdings, Inc., Revalesio Corp, Kinaset Therapeutics, Inc., Venatorx Pharmaceuticals, Inc., Cxl Ophthalmics, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.